Skip to main content

Myelofibrosis News

Related terms: Idiopathic myelofibrosis, Myeloid metaplasia, Agnogenic myeloid metaplasia, Primary myelofibrosis, Secondary myelofibrosis, MF

FDA Approves Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia

Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease,...

FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

SEATTLE, Feb. 28, 2022 /PRNewswire/ – CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved Vonjo (pacritinib) for the treatment of adults with...

FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients...

Ask a question

To post your own question to this support group, sign in or create an account.